MRVI Q2 2024 Earnings — Maravai LifeSciences Holdings, Inc. Revenue & Financial Results | Market Cap Arena

MRVIMaravai LifeSciences Holdings, Inc.

$999M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$73M+6.5% YoY

Gross Profit

$35M47.9% margin

Operating Income

-$10M-13.0% margin

Net Income

-$8M-10.3% margin

EPS (Diluted)

$-0.06

QoQ Revenue Growth

+14.4%

Cash Flow

Operating Cash Flow

$17M

Free Cash Flow

$8M

Stock-Based Comp.

$14M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$671M

Stockholders' Equity

$437M

Cash & Equivalents

$573M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$73M	$69M	+6.5%
Gross Profit	$35M	$26M	+37.0%
Operating Income	-$10M	-$12M	+18.1%
Net Income	-$8M	-$7M	-16.0%

Revenue Segments

Nucleic Acid Production Segment

$58M80%

Biologics Safety Testing Segment

$15M20%

Geographic Segments

North America

$32M44%

Asia Pacific

$23M32%

EMEA

$18M24%

Latin And Central America

$120,0000%